Dr. Luc Vallières is a Professor in the Department of Molecular Medicine at Laval University and a neuroimmunology researcher in the Neuroscience Unit at the CHU de Québec.

He began his career in 2002 after a postdoctoral training at the Salk Institute in California in the field of postnatal neurogenesis (1998-2001). This training was preceded by a doctorate in physiology at Laval University (1993-1998) and a bachelor’s degree in biology at the Université du Québec à Chicoutimi (1990-1993).

He is studying two diseases that afflict the central nervous system: multiple sclerosis and brain cancer. His research program aims to better understand how immune cells are regulated in these diseases in the hope of finding a way to neutralize or stimulate them for therapeutic purposes. This program is well funded by the CIHR, NSERC and Multiple Sclerosis Society of Canada.

He has made a significant contribution to the field of neuroimmunology by discovering a population of immune cells that constantly patrols the blood vessels of the nervous system and by elucidating mechanisms that govern their recruitment and functions under inflammatory conditions.

His research led to an international patent claiming the first ever drug that would specifically calm the neutrophil, an immune cell normally beneficial, but that can be involved in many inflammatory diseases.

His technical background includes single cell-RNA sequencing, STED super-resolution microscopy, flow cytometry, CRISPR-Cas9 gene editing and RNA interference, as well as bone marrow transplantation. Strong of this expertise, he directs the super-resolution microscopy and irradiation platforms at the CHU de Québec.

He is responsible of two courses, namely Principles of Neuroimmunology (MMO-7010) and Current Techniques in Molecular Medicine (MMO-7019).

Among his external activities, he is chairing the organizing committee of the 16th Congress of the International Society of Neuroimmunology, which will take place in Quebec City in August 2022. He is associate editor of the journal Mediators of Inflammation. He also serves on neuroscience committees at the CIHR.

CHUL
2705, boulevard Laurier
T2-41
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

38 entries « 1 of 4 »

Uyar O, Dominguez JM, Bordeleau M, Lapeyre L, Ibáñez FG, Vallières L, Tremblay ME, Corbeil J, Boivin G

Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response

Journal Article

J Neuroinflammation, 19 (1), 2022.

Abstract | Links:

Bérard M, Sheta R, Malvaut S, Rodriguez-Aller R, Teixeira M, Idi W, Turmel R, Alpaugh M, Dubois M, Dahmene M, Salesse C, Lamontagne-Proulx J, St-Pierre MK, Tavassoly O, Luo W, Del Cid-Pellitero E, Qazi R, Jeong JW, Durcan TM, Vallières L, Tremblay ME, Soulet D, Lévesque M, Cicchetti F, Fon EA, Saghatelyan A, Oueslati A

A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease

Journal Article

PLoS Biol, 20 (3), 2022.

Abstract | Links:

Joly S, Mdzomba JB, Rodriguez L, Morin F, Vallières L, Pernet V

B cell-dependent EAE induces visual deficits in the mouse with similarities to human autoimmune demyelinating diseases

Journal Article

J Neuroinflammation, 19 (1), 2022.

Abstract | Links:

Salem M, Lecka J, Pelletier J, Gomes Marconato D, Dumas A, Vallières L, Brochu G, Robaye B, Jobin C, Sévigny J

NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD

Journal Article

Gut, 71 (1), 2022.

Abstract | Links:

Morin F, Singh N, Mdzomba JB, Dumas A, Pernet V, Vallières L

Conditional Deletions of Confirm Roles of Histamine in Anaphylaxis and Circadian Activity but Not in Autoimmune Encephalomyelitis

Journal Article

J Immunol, 206 (9), 2021.

Abstract | Links:

El Hajj H, Savage JC, Bisht K, Parent M, Vallieres L, Rivest S, Tremblay ME

Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology

Journal Article

J Neuroinflammation, 16 (1), 2019.

Abstract | Links:

Morquette B, Juzwik CA, Drake SS, Charabati M, Zhang Y, Lecuyer MA, Galloway DA, Dumas A, de Faria Junior O, Paradis-Isler N, Bueno M, Rambaldi I, Zandee S, Moore C, Bar-Or A, Vallieres L, Prat A, Fournier AE

MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis

Journal Article

Brain, 142 (10), 2019.

Abstract | Links:

Whittaker Hawkins RF, Patenaude A, Dumas A, Jain R, Tesfagiorgis Y, Kerfoot S, Matsui T, Gunzer M, Poubelle PE, Larochelle C, Pelletier M, Vallieres L

ICAM1+ neutrophils promote chronic inflammation via ASPRV1 in B cell-dependent autoimmune encephalomyelitis

Journal Article

JCI Insight, 2 (23), 2017.

Abstract | Links:

Casserly CS, Nantes JC, Whittaker Hawkins RF, Vallieres L

Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine

Journal Article

Autoimmun Rev, 16 (3), 2017.

Abstract | Links:

Bisht K, Sharma KP, Lecours C, Sánchez MG, El Hajj H, Milior G, Olmos-Alonso A, Gomez-Nicola D, Luheshi G, Vallieres L, Branchi I, Maggi L, Limatola C, Butovsky O, Tremblay ME

Dark microglia: A new phenotype predominantly associated with pathological states

Journal Article

Glia, 64 (5), 2016.

Abstract | Links:

38 entries « 1 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Mécanisme d’action d’ASPRV1 dans l’inflammation, from 2021-04-01 to 2026-03-31
  • Plate-forme de production de nanoparticules lipidiques pour le développement de thérapies à base d'acides nucléiques, from 2022-03-22 to 2023-09-28
  • Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, from 2018-10-01 to 2023-03-31

Recently finished projects

  • Characterization of a novel dendritic cell-specific protein in demyelinating autoimmune diseases, from 2019-04-01 to 2022-03-31
  • Évaluation du rôle de l'aspartic peptidase ASPRV1 dans l'asthme, from 2019-12-01 to 2020-11-30
  • Production et caractérisation d'anticorps anti-ASPRV1 pour le traitement de maladies immunitaires, from 2019-09-25 to 2020-06-30
  • Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, from 2018-04-01 to 2021-03-31
Data provided by the Université Laval research projects registery